Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a ...
BOSTON--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, announced new data validating the ...
Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...
Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...
Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...
On the third day of the J.P. Morgan Healthcare Conference, Arbor Biotechnologies and Vertex Pharmaceuticals announced that they would be expanding into reverse transcription-based in vivo genetic ...
Rome Therapeutics Inc. has presented data demonstrating the potential of its LINE-1 reverse transcriptase (RT) inhibitors as a novel treatment for neurodegenerative diseases.
Evaluation of gene expression signatures induced by stromal factors as a predictor of survival in breast cancer. Methods: This was a retrospective study of 116 patients with ductal invasive breast ...
Jerold Chun, MD, PhD, is a professor in the Center for Neurologic Diseases at Sanford Burnham Prebys and the senior and corresponding author of the manuscript. Alzheimer’s disease is the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results